Annalise CXR approved for clinical use in Australia and New Zealand
Australian medical imaging artificial intelligence company annalise.ai has successfully registered Annalise CXR on the Australian Register of Therapeutic Goods (ARTG) and Medsafe in New Zealand.
Australian medical imaging artificial intelligence company annalise.ai has successfully registered Annalise CXR as a medical device with the New Zealand Medicines and Medical Devices Safety Authority and a class 1 medical device on the Australian Register of Therapeutic Goods, making it available for clinical use.
Annalise CXR is the company’s first comprehensive AI solution assisting clinicians to interpret chest x-ray studies by detecting 124 findings, providing clinicians with another set of eyes that providing assurance and support when it’s needed most.
Annalise.ai CEO Dimitry Tran said: “As an Australian business we are pleased to hear that Annalise CXR met the medical device standards of Australia and New Zealand. We are pleased to be able to offer our solution to the region and look forward to rolling out nationwide in the coming months.”
In addition to Australia and New Zealand, Annalise CXR has the CE mark for clinical use in the UK and EU.
Annalise CXR is the first comprehensive solution developed by annalise.ai.